Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.11 Analyst target: $8.55 Upside: 670.27%
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
See the full interactive analysis & chart →Informational only — not investment advice.